|
| Tuesday, April 20, 2021 |
|
|
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. more info >> |
|
| Wednesday, April 14, 2021 |
|
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
|
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2021年4月17日から22日までバーチャルで開催される「米国神経学会（American Academy of Neurology）年次総会：AAN2021」において、抗アミロイドB（AB）プロトフィブリル抗体lecanemab（開発品コード：BAN2401）、デュアルオレキシン受容体拮抗剤レンボレキサント（製品名「デエビゴ(R)」、海外製品名「Dayvigo(R)」）および抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、海外製品名「Fycompa(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Monday, April 12, 2021 |
|
|
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、リンパ系フィラリア症（LF）の制圧活動をテーマとして当社が制作したアニメーション動画「Leave No One Behind―顧みられない人々の病気―」が、International Society for Neglected Tropical Diseases （ISNTD）フェスティバルアワード 2021 の「アニメーション賞」を受賞したことをお知らせします。 more info >> |
|
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
| Wednesday, March 31, 2021 |
|
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
| KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
| Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
|
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩（製品名：「レンビマ(R)」、「Kisplyx(R)」、以下 レンバチニブ）について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.（北米以外ではMSD）の抗PD-1抗体ペムブロリズマブ（製品名：「キイトルーダ(R)」、以下 ペムブロリズマブ）との併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る適応追加の申請をそれぞれ行い、欧州医薬品庁によって受理されましたのでお知らせします。 more info >> |
|
| Friday, March 26, 2021 |
|
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
|
|
|
